SEC Info - Nymox Pharmaceutical Corp - ‘20-F’ for 12/31/08

SEC Info℠

Home

Help

Please Sign In

Nymox Pharmaceutical Corp – ‘20-F’ for 12/31/08 – ‘EX-13.(B)’

On: Friday, 3/13/09, at 12:54pm ET · For: 12/31/08 · Accession #: 1176256-9-225 · File #: 1-12033

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 3/13/09  Nymox Pharmaceutical Corp         20-F       12/31/08    5:1.2M                                   e3 Fil… Computershare/FA

Annual Report by a Foreign Private Issuer — Form 20-F
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 20-F        Annual Report by a Foreign Private Issuer           HTML   1.06M 
 4: EX-13.(A)   Annual or Quarterly Report to Security Holders      HTML      7K 
 5: EX-13.(B)   Annual or Quarterly Report to Security Holders      HTML      7K 
 2: EX-12.(A)   Statement re: Computation of Ratios                 HTML     11K 
 3: EX-12.(B)   Statement re: Computation of Ratios                 HTML     11K

EX-13.(B) — Annual or Quarterly Report to Security Holders

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

Exhibit 12 (d)

<> <> <>

Exhibit 13 (b)

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Roy Wolvin, CFO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report on Form 20-F for the year ended December 31, 2008 of Nymox Pharmaceutical Corporation and filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 and the information contained in such report fairly presents, in all material respects, the financial condition and results of operations on Nymox Pharmaceutical Corporation.

Date: March 13, 2009

/s/ Roy Wolvin

Roy Wolvin

Chief Financial Officer

Nymox Pharmaceutical Corporation

Dates Referenced Herein and Documents Incorporated by Reference

This ‘20-F’ Filing	Date	Other Filings

Filed on:	3/13/09	6-K
For Period End:	12/31/08
		List all Filings

↑Top

Filing Submission 0001176256-09-000225 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)